Evaluating the Role of Biosimilars in the Management of Rheumatologic Conditions

Join us for a fun and interactive CME-certified quiz game symposium at the 2017 ACR/ARHP Annual Meeting! This quiz-based challenge will feature in-depth presentations and expert discussion on integrating biosimilars into rheumatology practice.


1:30 PM    Welcome and Program Overview
Chair: Stanley B. Cohen, MD

1:40 PM    Quiz Round 1: Insights into Biosimilar Development and Evaluation
Faculty: Stanley B. Cohen, MD

2:00 PM    Quiz Round 2: Understanding the Landscape of Rheumatology Biosimilars
Faculty: Kenneth G. Saag, MD, MSc

2:20 PM    Quiz Round 3: Integrating Biosimilars into Rheumatology Practice
Faculty: Jonathan Kay, MD

2:40 PM    Bonus Round and Question and Answer Session
Faculty Panel

3:00 PM    Adjournment


Date / Time
Event Details


Program Director
Stanley B. Cohen, MD

Clinical Professor 
Department of Internal Medicine
University of Texas Southwestern Medical School
Division of Rheumatology
Presbyterian Hospital
Co-Medical Director
Metroplex Clinical Research Center
Dallas, Texas

Jonathan Kay, MD

Professor of Medicine
Timothy S. and Elaine L. Peterson Chair in Rheumatology
Division of Rheumatology
Department of Medicine
University of Massachusetts Medical School
Division of Rheumatology
Department of Medicine
UMass Memorial Medical Center
Worcester, Massachusetts

Kenneth Saag, MD

Jane Knight Lowe Professor
Division of Clinical Immunology and Rheumatology
Vice Chair, Department of Medicine
Center for Education and Research on Therapeutics
Center for Outcomes, Effectiveness Research and Education
Center of Research Translation in Gout and Hyperuricemia
University of Alabama at Birmingham
Birmingham, Alabama


Goal Statement
The goal of this activity is to improve rheumatologists’ and other clinicians’ understanding of biosimilars and their safe and appropriate use in the care of patients with rheumatologic conditions

Target Audience
This program is intended for rheumatologists, primary care physicians, nurse practitioners, physician assistants, registered nurses, pharmacists, and other healthcare professionals who are involved in the care of patients with rheumatologic conditions.

Learning Objectives
At the conclusion of this activity, participants should be able to:

  • Compare and contrast biosimilars, reference biologics, and small molecule generics with indications for rheumatologic conditions
  • Compare available safety and efficacy data for the use of biosimilars and their reference biologics in the management of rheumatologic conditions
  • Outline the potential impact of interchangeability, extrapolation of indications, and substitution on dose/response, adverse events, and clinical outcomes
  • Summarize the key steps required by the FDA to demonstrate biosimilarity between a biosimilar and its reference biologic
  • Compare the regulatory approval pathways for small molecule generics, biologic agents, and biosimilars


Physician Continuing Education

Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and Clinical Care Options, LLC. Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
Postgraduate Institute for Medicine designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.